NCT04791514终止2 期
An Open-Label Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 1
- 试验地点
- 1
- 主要终点
- Number of Participants Who Experience a Treatment Emergent Adverse Event (TEAE)
研究概览
简要总结
The main purpose of this study is to evaluate the safety and tolerability of single dose of treprostinil palmitil inhalation powder (TPIP) in participants with pulmonary arterial hypertension (PAH).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participant must be ≥ 18 years of age at the time of signing the informed consent
- •Participants must have a diagnosis of World Health Organization Group 1 Pulmonary Hypertension (PH) (PAH) with the following characteristics
- •Etiology of idiopathic, heritable, drug/toxin-induced or connective tissue disease (CTD)-related PAH
- •Right heart catheterization with the following hemodynamic findings:
- •Mean pulmonary arterial pressure (mPAP) > 20 mmHg at rest,
- •Pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg, and
- •Pulmonary vascular resistance (PVR) of ≥ 3 Wood Units (WU)
- •No change in pulmonary hypertension medications (eg, ambrisentan, bosentan, macitentan, sildenafil, tadalafil, riociguat) or dosage for at least 90 days prior to Screening
- •No change in diuretic use or dosage for at least 30 days prior to Screening
- •Body mass index (BMI) within the range 18.0 - 32.0 kg/m^2 (inclusive)
- •Male participants: Male participants and their female partners of childbearing potential must agree to use highly effective contraception from Study Day 1 to at least 90 days after dosing
- •Female participants: Women of child-bearing potential (WOCPB, defined as premenopausal, not surgically sterile for at least 3 months prior to Screening) must use a highly effective contraception method and agree to be tested for pregnancy from at Screening, Baseline, and 30 days after dosing
- •Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol.
排除标准
- •Any PH other than idiopathic, hereditary, drug/toxin-induced, or connective tissue disease (CTD) associated PAH (eg, congenital heart disease-associated PAH, portal hypertension-associated PAH, PH belonging to Groups 2 through 5)
- •Allergy, or documented hypersensitivity or contraindication, to the ingredients of treprostinil palmitil inhalation powder (TPIP) or treprostinil (TRE)
- •Previous intolerance to prostacyclin analogs or receptor agonists (eg, selexipag) per investigator discretion
- •History of anaphylaxis or previously documented hypersensitivity reaction to any drug per Investigator discretion
- •History of heart disease including left ventricular ejection fraction (LVEF) ≤ 40% or clinically significant valvular, constrictive, or atherosclerotic heart disease (myocardial infarction, etc)
- •Active liver disease or hepatic dysfunction manifested as:
- •Elevated liver function test results (ALT or AST > 2 × ULN) at Screening
- •Bilirubin > 1.5 × ULN (isolated bilirubin > 1.5 × ULN; ULN is acceptable if bilirubin is fractionated and direct bilirubin < 35%) at Screening.
- •Known hepatic or biliary abnormalities, not including Gilbert's syndrome or asymptomatic gallstones at Screening.
- •History of HIV infection/positive HIV serology test result at Screening
- •History of active/chronic Hepatitis B or C/ positive hepatitis B or C serology test result at Screening
- •History of abnormal bleeding or bruising
- •Known or suspected immunodeficiency disorder, including history of invasive opportunistic infections (eg, tuberculosis, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis) despite infection resolution, or otherwise recurrent infections of abnormal frequency, or prolonged infections suggesting an immune-compromised status, as judged by the investigator
- •Active and current symptomatic infection by SARS CoV 2
- •Participants with current or recent (past 4 weeks) lower respiratory tract infection
- •History of malignancy in the past 5 years, with exception of completely treated in situ carcinoma of the cervix and completely treated non-metastatic squamous or basal cell carcinoma of the skin
- •Participants receiving triple combination therapy for PAH consisting of endothelin receptor agonists, phosphoesterase type 5 inhibitors, and guanylate cyclase stimulators (riociguat)
- •Participants receiving prostanoids/prostacyclin agonists
- •Participants receiving potent CYP2C8 inhibitors, such as gemfibrozil
- •Have participated in any other interventional clinical studies within 30 days of Baseline
- •Current or history of substance and/or alcohol abuse
- •Current user of cigarettes or e-cigarettes
- •Pregnant or breastfeeding
研究组 & 干预措施
Treprostinil Palmitil Inhalation Powder
Experimental
Participant received a single dose of TPIP 112.5 micrograms (μg) via oral inhalation on Day 1. The participant then entered into a 16-week Extended Use Treatment (EUT) Period during which TPIP, administered via oral inhalation, was titrated up to a mean daily dose of 320 μg.
干预措施: Treprostinil Palmitil (Drug)
结局指标
主要结局
Number of Participants Who Experience a Treatment Emergent Adverse Event (TEAE)
时间窗: Up to 150 days
次要结局
- Time to Maximum Concentration (Tmax) of Treprostinil (TRE) in Plasma(Pre-dose and multiple timepoints post-dose up to Day 2)
- Maximum Observed Concentration (Cmax) of Treprostinil (TRE) in Plasma(Pre-dose and multiple timepoints post-dose up to Day 2)
- Change From Baseline in Pulmonary Vascular Resistance (PVR) After TPIP Administration(Day 1: Pre-treatment (Baseline), 8 and 24 hours post-treatment)
- Area Under the Concentration-time Curve From Time 0 to Time of the Last Measurable Concentration (AUClast) of Treprostinil (TRE) in Plasma(Pre-dose and multiple timepoints post-dose up to Day 2)
- Elimination Half-life (t1/2) of Treprostinil (TRE) in Plasma(Pre-dose and multiple timepoints post-dose up to Day 2)
- Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-∞) of Treprostinil (TRE) in Pasma(Pre-dose and multiple timepoints post-dose up to Day 2)
研究者
研究点 (1)
Loading locations...
相似试验
撤回
2 期
A Pharmacokinetics and Safety Study of Augmentin ES-600 in Children With CAP and ABRSInfections, BacterialNCT05340257GlaxoSmithKline24
已完成
1 期
Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal FunctionFabry DiseaseNCT01730469Amicus Therapeutics32
已完成
1 期
Study To Evaluate The Effect Of Renal Impairment On The Pharmacokinetics Of PF-04991532HealthyType 2 Diabetes MellitusNCT01369602Pfizer27
终止
2 期
An Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of JNJ-17299425 in Participants With Traumatic Brain InjuryTraumatic Brain InjuryNCT01814982Johnson & Johnson Pharmaceutical Research & Development, L.L.C.7
已完成
1 期
A Ph 1 Study of Epanova® in Healthy ChinesesHealthy SubjectsNCT03574142AstraZeneca14